|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9-10
|
|
pubmed:dateCreated |
2008-5-12
|
|
pubmed:abstractText |
Declining productivity with decreasing new molecular entity output combined with increased R&D spending is one of the key challenges for the entire pharmaceutical industry. In order to offset decreasing new molecular entity output, life-cycle management activities for established drugs become more and more important to maintain or even expand clinical indication and market opportunities. Life-cycle management covers a whole range of activities from strategic pricing to a next generation product launch. In this communication, we review how research organizations can contribute to successful life-cycle management strategies using phosphodiesterase 5 inhibitors as an example.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1359-6446
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
457-63
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18468564-Animals,
pubmed-meshheading:18468564-Biological Agents,
pubmed-meshheading:18468564-Biomedical Research,
pubmed-meshheading:18468564-Chemistry, Pharmaceutical,
pubmed-meshheading:18468564-Drug Approval,
pubmed-meshheading:18468564-Drug Combinations,
pubmed-meshheading:18468564-Drug Industry,
pubmed-meshheading:18468564-Humans,
pubmed-meshheading:18468564-Intellectual Property,
pubmed-meshheading:18468564-Phosphodiesterase 5 Inhibitors,
pubmed-meshheading:18468564-Phosphodiesterase Inhibitors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Product-related research: how research can contribute to successful life-cycle management.
|
|
pubmed:affiliation |
Bayer HealthCare AG, Global Drug Discovery, Germany. peter.sandner@bayerhealthcare.com
|
|
pubmed:publicationType |
Journal Article,
Review
|
